GlassScriptPhysician profile
Lori Danielle Smith
NPI 1639282692
$864.83
in general payments reported to CMS, 2019-2025
18 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.63 · 2020: $33.93 · 2022: $48.78 · 2023: $206 · 2024: $436 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $155.47 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $128.67 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $123.65 | 2023-2024 | |
| Optinose US, INC. | $49.56 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $48.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $43.20 | 2023 | Quviviq |
| Exact Sciences Corporation | $39.53 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $29.25 | 2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $29.09 | 2024 | Spravato |
| Viiv Healthcare Company | $29.02 | 2025 | Apretude |
| Amgen INC. | $28.86 | 2024 | Evenity, Prolia |
| Abbvie INC. | $28.47 | 2023 | Vraylar |
| Baxter Healthcare | $27.62 | 2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Abbott Laboratories | $27.13 | 2025 | Eterna |
| Organon LLC | $24.95 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.56 | 2024 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $17.32 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $15.70 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.